ENDOTOXIN ADMINISTRATION TO HUMANS INHIBITS HEPATIC CYTOCHROME P450-MEDIATED DRUG-METABOLISM

被引:175
作者
SHEDLOFSKY, SI
ISRAEL, BC
MCCLAIN, CJ
HILL, DB
BLOUIN, RA
机构
[1] UNIV KENTUCKY,COLL MED,DIV DIGEST DIS,LEXINGTON,KY 40506
[2] UNIV KENTUCKY,COLL PHARM,LEXINGTON,KY
[3] UNIV KENTUCKY,COLL MED,GEN CLIN RES CTR,LEXINGTON,KY 40511
关键词
CYTOKINES; INFLAMMATION; SEPSIS; TUMOR NECROSIS FACTOR; LIPOPOLYSACCHARIDE;
D O I
10.1172/JCI117582
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In experimental animals, injection of gram-negative endotoxin (LPS) decreases hepatic cytochrome P450-mediated drug metabolism. To evaluate this phenomenon in a human model of gram-negative sepsis, LPS was administered on two consecutive days to healthy male volunteers during which time a cocktail of antipyrine (AP-250 mg), hexobarbital (HB-500 mg), and theophylline (TH-150 mg) was ingested and the apparent oral clearance of each drug determined. Each subject had a control drug clearance study with saline injections. In the first experiment, six subjects received the drug cocktail 0.5 h after the first dose of LPS. In the second experiment, another six subjects received the drug cocktail 0.5 h after the second dose of LPS. In both experiments, LPS caused the expected physiologic responses of inflammation including fever with increases in serum concentrations of TNF alpha, IL-1 beta, IL-6, and acute phase reactants. In the first experiment, only minor decreases in clearances of the probe drugs were observed (7-12%). However in the second experiment, marked decreases in the clearances of AP (35, 95% CI 18-48%), HB (27, 95% CI 14-34%), and TH (22, 95% CI 12-32%) were seen. The decreases in AP clearance correlated with initial peak values of TNF alpha (r = 0.82) and IL-6 (r = 0.86). These data show that in humans the inflammatory response to even a very low dose of LPS significantly decreases hepatic cytochrome P450-mediated drug metabolism and this effect evolves over a 24-h period. It is likely that septic patients with much higher exposures to LPS have more profound inhibition of drug metabolism.
引用
收藏
页码:2209 / 2214
页数:6
相关论文
共 41 条
  • [1] DEPRESSION OF LIVER DRUG-METABOLISM AND INCREASE IN PLASMA-FIBRINOGEN BY INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR - A COMPARISON WITH LYMPHOTOXIN AND INTERFERON
    BERTINI, R
    BIANCHI, M
    VILLA, P
    GHEZZI, P
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1988, 10 (05): : 525 - 530
  • [2] BERTINI R, 1989, J LEUKOCYTE BIOL, V46, P354
  • [3] BOLTON S, 1990, PHARM STAT PRACTICAL, P496
  • [4] A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) : 653 - 658
  • [5] EXPRESSION OF A HUMAN-LIVER CYTOCHROME-P-450 PROTEIN WITH TOLBUTAMIDE HYDROXYLASE-ACTIVITY IN SACCHAROMYCES-CEREVISIAE
    BRIAN, WR
    SRIVASTAVA, PK
    UMBENHAUER, DR
    LLOYD, RS
    GUENGERICH, FP
    [J]. BIOCHEMISTRY, 1989, 28 (12) : 4993 - 4999
  • [6] EFFECTS OF INTERLEUKIN-6 ON CYTOCHROME-P450-DEPENDENT MIXED-FUNCTION OXIDASES IN THE RAT
    CHEN, YL
    FLORENTIN, I
    BATT, AM
    FERRARI, L
    GIROUD, JP
    CHAUVELOTMOACHON, L
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 44 (01) : 137 - 148
  • [7] ENDOTOXEMIA IN HUMAN SEPTIC SHOCK
    DANNER, RL
    ELIN, RJ
    HOSSEINI, JM
    WESLEY, RA
    REILLY, JM
    PARILLO, JE
    [J]. CHEST, 1991, 99 (01) : 169 - 175
  • [8] ELIN RJ, 1975, CLIN PHARMACOL THER, V17, P447
  • [9] BIOTRANSFORMATION OF CAFFEINE AND THEOPHYLLINE IN MAMMALIAN-CELL LINES GENETICALLY ENGINEERED FOR EXPRESSION OF SINGLE CYTOCHROME-P450 ISOFORMS
    FUHR, U
    DOEHMER, J
    BATTULA, N
    WOLFEL, C
    KUDLA, C
    KEITA, Y
    STAIB, AH
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 43 (02) : 225 - 235
  • [10] ROLE OF INTERLEUKIN-1 IN THE DEPRESSION OF LIVER DRUG-METABOLISM BY ENDOTOXIN
    GHEZZI, P
    SACCARDO, B
    VILLA, P
    ROSSI, V
    BIANCHI, M
    DINARELLO, CA
    [J]. INFECTION AND IMMUNITY, 1986, 54 (03) : 837 - 840